Koss Olinger Consulting LLC Grows Position in Eli Lilly and Company (NYSE:LLY)

Koss Olinger Consulting LLC lifted its stake in shares of Eli Lilly and Company (NYSE:LLY) by 11.9% in the 2nd quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 3,263 shares of the company’s stock after buying an additional 347 shares during the period. Koss Olinger Consulting LLC’s holdings in Eli Lilly and were worth $749,000 at the end of the most recent quarter.

Other institutional investors and hedge funds also recently made changes to their positions in the company. Price T Rowe Associates Inc. MD raised its stake in Eli Lilly and by 116.3% in the 1st quarter. Price T Rowe Associates Inc. MD now owns 26,155,001 shares of the company’s stock worth $4,886,278,000 after acquiring an additional 14,060,388 shares during the last quarter. Jennison Associates LLC raised its stake in shares of Eli Lilly and by 189.5% in the first quarter. Jennison Associates LLC now owns 5,440,137 shares of the company’s stock worth $1,016,326,000 after purchasing an additional 3,561,294 shares during the last quarter. AMF Pensionsforsakring AB acquired a new stake in shares of Eli Lilly and during the second quarter worth about $240,526,000. Ameriprise Financial Inc. boosted its position in Eli Lilly and by 12.2% in the first quarter. Ameriprise Financial Inc. now owns 8,349,657 shares of the company’s stock valued at $1,560,069,000 after buying an additional 908,748 shares during the last quarter. Finally, Mn Services Vermogensbeheer B.V. acquired a new position in Eli Lilly and in the 2nd quarter worth approximately $115,618,000. 81.65% of the stock is currently owned by hedge funds and other institutional investors.

NYSE LLY opened at $231.64 on Tuesday. The company has a debt-to-equity ratio of 2.21, a current ratio of 1.15 and a quick ratio of 0.89. The stock’s 50 day simple moving average is $251.58 and its 200-day simple moving average is $219.36. The company has a market cap of $222.15 billion, a PE ratio of 34.73, a price-to-earnings-growth ratio of 1.86 and a beta of 0.25. Eli Lilly and Company has a 1-year low of $129.21 and a 1-year high of $275.87.

Eli Lilly and (NYSE:LLY) last posted its quarterly earnings data on Monday, August 2nd. The company reported $1.87 EPS for the quarter, missing the Thomson Reuters’ consensus estimate of $1.89 by ($0.02). Eli Lilly and had a net margin of 22.71% and a return on equity of 119.12%. The firm had revenue of $6.74 billion during the quarter, compared to analyst estimates of $6.59 billion. During the same period in the prior year, the company posted $1.89 earnings per share. The firm’s revenue for the quarter was up 22.6% compared to the same quarter last year. On average, equities research analysts anticipate that Eli Lilly and Company will post 7.87 EPS for the current fiscal year.

The firm also recently declared a quarterly dividend, which was paid on Friday, September 10th. Stockholders of record on Friday, August 13th were paid a $0.85 dividend. This represents a $3.40 annualized dividend and a dividend yield of 1.47%. The ex-dividend date of this dividend was Thursday, August 12th. Eli Lilly and’s dividend payout ratio is currently 42.88%.

In related news, major shareholder Lilly Endowment Inc sold 3,060 shares of the company’s stock in a transaction dated Tuesday, August 17th. The shares were sold at an average price of $274.08, for a total transaction of $838,684.80. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link. Insiders have sold 1,044,132 shares of company stock worth $257,735,592 over the last 90 days. 0.13% of the stock is currently owned by company insiders.

A number of research firms have recently weighed in on LLY. Truist Securities increased their price objective on shares of Eli Lilly and from $225.00 to $262.00 and gave the stock a “buy” rating in a research note on Friday, July 2nd. Barclays increased their price target on Eli Lilly and from $227.00 to $250.00 and gave the stock an “overweight” rating in a research report on Tuesday, July 6th. Cantor Fitzgerald upped their target price on Eli Lilly and from $245.00 to $300.00 and gave the stock an “overweight” rating in a research note on Thursday, June 24th. Truist Financial reiterated a “buy” rating and set a $225.00 price target on shares of Eli Lilly and in a research report on Tuesday, June 8th. Finally, The Goldman Sachs Group upped their price objective on Eli Lilly and from $252.00 to $270.00 and gave the stock a “conviction-buy” rating in a research report on Monday, June 14th. One research analyst has rated the stock with a sell rating, two have issued a hold rating, thirteen have issued a buy rating and one has assigned a strong buy rating to the company’s stock. According to data from MarketBeat.com, Eli Lilly and presently has an average rating of “Buy” and an average target price of $250.41.

Eli Lilly and Profile

Eli Lilly & Co engages in the discovery, development, manufacture and sale of pharmaceutical products. The firm’s products consist of Diabetes, Oncology, Immunology, Neuroscience, and Other therapies. The Diabetes products include Baqsimi, Basaglar, Humalog, Humulin, Jardiance, Lyumjev, Trajenta, and Trulicity.

Further Reading: How is a management fee different from a performance fee?

Want to see what other hedge funds are holding LLY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Eli Lilly and Company (NYSE:LLY).

Institutional Ownership by Quarter for Eli Lilly and (NYSE:LLY)

Receive News & Ratings for Eli Lilly and Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eli Lilly and and related companies with MarketBeat.com's FREE daily email newsletter.